Tae-Ho Hwang - Concepedia

Author

Tae-Ho Hwang

Also Known As

Dong Ju Kang, Euna Cho, Soon-Woo Jang, T. Hwang, T.-H. Hwang, T.H. Hwang, Tae-Ho H. Hwang, Tae-Ho Hwang, Taeho Hwang, Theodore Hwang

104

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Pusan National University Dong-A University University of Ottawa Ottawa Hospital Pusan National University Yangsan Hospital

About

Tae-Ho Hwang is an author at Pusan National University specializing in medicine, hepatology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	2.2K
2	Engineering	4	4	89
3	Health Sciences	3	3	1.3K
4	Social Sciences	2	2	62
5	Biomedical Engineering	1	1	10

Tae-Ho Hwang

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
<i>Cbfa1</i>-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor Masaki Kato, Millan S. Patel, Régis Levasseur, The Journal of Cell Biology Osteoblast ProliferationImmunologyCell DeathHuman Osteoporosis-pseudoglioma SyndromeCellular Physiology	2002	1.1K
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial Byeong-Ho Park, Tae-Ho Hwang, Ta‐Chiang Liu, The Lancet Oncology Metastatic Liver CancerHepatologyMedicinePathologyVirology	2008	514
The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers Kelley A. Parato, Caroline J. Breitbach, Fabrice Le Bœuf, Molecular Therapy	2011	300
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF J.H. Kim, Joe Oh, B.H. Park, Molecular Therapy	2006	299
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Cancer Research	2013	250
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963 Steve H. Thorne, Tae-Ho Hwang, William O’Gorman, Journal of Clinical Investigation Synthetic VirologyViral PathogenesisImmunologyImmunotherapyTumor Biology	2007	197
The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma Ta‐Chiang Liu, Tae-Ho Hwang, Byeong-Ho Park, Molecular Therapy	2008	189
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma Tae-Ho Hwang, Anne Moon, James M. Burke, Molecular Therapy	2011	157
Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients Timothy P. Cripe, Minhtran Ngo, James I. Geller, Molecular Therapy	2014	156
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy Jeong Heo, Caroline J. Breitbach, Anne Moon, Molecular Therapy Concurrent SorafenibImmunologyImmunoeditingPathologyImmunotherapy	2011	143

Page 1